Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 212
- Registration Number
- NCT03665610
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 560
- Registration Number
- NCT03647124
- Locations
- 🇬🇷
Local Institution - 511, Rio, Patras, Greece
🇬🇷Theageneio General Hospital, Thessaloniki, Thessaloniki, Greece
🇬🇷Metaxa Cancer Hospital, Athens, Piraeous, Greece
Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate
- Conditions
- Interventions
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 54
- Registration Number
- NCT03644576
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT03624959
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
- Conditions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 706
- Registration Number
- NCT03602755
- Locations
- 🇪🇸
H. Central de Asturias, Oviedo, Asturias, Spain
🇪🇸H. Cabueñes, Gijón, Asturias, Spain
🇪🇸H. Althaia, Manresa, Barcelona, Spain
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 264
- Registration Number
- NCT03601078
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 184
- Registration Number
- NCT03575351
- Locations
- 🇺🇸
Loyola University Medical Center Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸Local Institution - 109, Dallas, Texas, United States
🇧🇪Local Institution - 350, Gent, Belgium
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 97
- Registration Number
- NCT03554993
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, United Kingdom
A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease
- Conditions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 5
- Registration Number
- NCT03521180
- Locations
- 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸Covance, Dallas, Texas, United States